News
INVO Bioscience Enters Distribution Agreement for Taiwan
SARASOTA, Fla., Jan. 5, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC")...
INVO Bioscience Reports Third Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Nov. 14, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®...
INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Nov. 10, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide...
INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. - The INVOcell solution...
INVOcell Review Published in Current Opinion in Obstetrics and Gynecology
SARASOTA, Fla., Oct. 21, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables,...
INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
SARASOTA, Fla. and ANAHEIM, Calif., Oct. 17, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for...
Dr. Sue Ellen Carpenter of INVO Bioscience’s Atlanta-based INVO Center – Bloom Fertility – Named Top Doctor by Castle Connolly
SARASOTA, Fla. and ATLANTA, Sept. 22, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure...
INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz
SARASOTA, Fla., Aug. 25, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables,...
INVO Bioscience Reports Second Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 15, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®...
INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 4, 2022 -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide...